中国引入Vaccae疫苗与强化耐药结核管理策略的健康和经济影响
该研究用经全国结核数据校准的房室模型评估9种干预措施。结果显示强化耐药结核管理(S1)到2050年可降低耐多药/利福平耐药结核发病21%和死亡54%;对老年人接种Vaccae联合S1(S9)更有效,发病降低44%、死亡降低68%,ICER为每避免1个DALY 7222美元。作者认为优先为老年人接种Vaccae并强化耐药结核管理是具有成本效益的机会。
要点
- 强化耐药结核管理(S1)预计到2050年降低耐多药/利福平耐药结核发病21%、死亡54%。
- 对老年人接种Vaccae联合S1(S9)降低发病44%、死亡68%,ICER为每避免1个DALY 7222美元。
核心结论
- 优先为老年人接种Vaccae并强化耐药结核管理对中国而言是有前景且具成本效益的机会。
- 研究结果可能对耐多药/利福平耐药结核负担高的其他中低收入国家有政策启示。
研究设计与样本
- 使用经全国结核数据校准的房室模型,评估9种干预措施:S1为强化耐药结核管理;S2至S5为针对特定年龄组(青少年、青少年和年轻成人、工作年龄成人、老年人)的潜伏结核感染Vaccae接种;S6至S9为联合策略。
- Vaccae效力在最初5年为0.547,之后逐年衰减;Vaccae成本为每剂28美元,Xpert MTB/RIF检测为每次87美元,BPaLM为每疗程13818美元。
主要发现
- S1预计到2050年降低耐多药/利福平耐药结核发病21%(95% UI,8%-46%)、死亡54%(38%-67%)。
- S9(S5+S1)较S1更有效,降低发病44%(35%-61%)、死亡68%(52%-78%),ICER为每避免1个DALY 7222美元(4460-10779)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: China faces high burden of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). We aimed to evaluate the impacts of Vaccae vaccination and enhanced drug-resistant TB (DR-TB) management strategies. METHODS: Using a compartmental model calibrated with national TB data, we evaluated 9 interventions: enhanced DR-TB management (S1); Vaccae vaccination for those with latent TB infection, targeting specific age groups (S2: adolescents, S3: adolescents and young adults, S4: working-age adults, S5: elderly); and combined strategies S6-S9. Vaccae's efficacy was 0.547 for the first 5 years, then waning annually. Costs were US$28/dose for Vaccae, US$87/test for Xpert MTB/RIF, and US$13 818/course for BPaLM. RESULTS: Strategy S1 is projected to reduce MDR/RR-TB incidence and mortality by 21% (95% UI, 8%-46%) and 54% (38%-67%), respectively, by 2050. Strategy S9 (S5+S1) is more effective, reducing the incidence by 44% (35%-61%) and mortality by 68% (52%-78%), with an ICER of US$7222 (4460-10 779) per DALY averted compared with S1. Additionally, S9 could prevent 24.2 (13.5-32.9) million patient-months of second-line treatment from 2025 to 2050. CONCLUSIONS: Prioritizing Vaccae vaccination for the elderly and enhancing DR-TB management offer a promising and cost-effective opportunity for China. The findings may have policy implications for other low- and middle-income countries with high MDR/RR-TB burden.
引用
- Zhai PY, Zang X, Jiang T, et al. Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China. J Infect Dis. 2025. PMID: 39576253. doi:10.1093/infdis/jiae590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。